1099 related articles for article (PubMed ID: 28763044)
1. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
2. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
Lu J; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
[TBL] [Abstract][Full Text] [Related]
3. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
[TBL] [Abstract][Full Text] [Related]
6. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
7. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
10. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
11. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
12. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
Pillow TH
Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
[TBL] [Abstract][Full Text] [Related]
13. Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs).
Yao H; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848651
[TBL] [Abstract][Full Text] [Related]
14. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.
Strop P; Liu SH; Dorywalska M; Delaria K; Dushin RG; Tran TT; Ho WH; Farias S; Casas MG; Abdiche Y; Zhou D; Chandrasekaran R; Samain C; Loo C; Rossi A; Rickert M; Krimm S; Wong T; Chin SM; Yu J; Dilley J; Chaparro-Riggers J; Filzen GF; O'Donnell CJ; Wang F; Myers JS; Pons J; Shelton DL; Rajpal A
Chem Biol; 2013 Feb; 20(2):161-7. PubMed ID: 23438745
[TBL] [Abstract][Full Text] [Related]
15. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the construction of antibody-drug conjugates.
Chudasama V; Maruani A; Caddick S
Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
[TBL] [Abstract][Full Text] [Related]
18. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
Frigerio M; Kyle AF
Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: Current status and future perspectives.
Gébleux R; Casi G
Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]